Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 37

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 37
---
 solely upon a review of the
Forms 3, 4 and 5 and amendments thereto furnished to the Company, we believe that all directors, executive officers and persons beneficially
owning greater than 10% of the Company’s equity securities timely filed reports required by Section 16(a) of the Exchange Act during
fiscal year 2024.

<div align='center'>PROPOSAL 2:
ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION
AS DISCLOSED IN THIS PROXY STATEMENT</div>

We are seeking your advisory vote
as required by Section 14A of the Securities Exchange Act of 1934, as amended, on the approval of the compensation of our named executive
officers as described in the Executive Officer and Director Compensation section, the compensation tables and related material contained
in this proxy statement. Because your vote is advisory, it will not be binding on our Compensation Committee or our Board. However, the
Compensation Committee and our Board will review the voting results and take them into consideration when making future decisions regarding
executive compensation. We have determined to hold an advisory vote to approve the compensation of our named executive officers annually,
and the next such advisory vote will occur at the 2026 annual meeting.

As a Nasdaq listed company in the competitive biotechnology
space, we believe that an affordable, market-competitive blend of base salary, short-term incentives and long-term incentives is key to
our success. Our intent is to maintain a compensation program designed to align, reinforce and support our mission, values and business
strategy. Our executive compensation program is designed to attract, motivate, reward and retain the senior management talent capable
of delivering on our strategy and goals. We believe that our compensation programs are centered on pay-for-performance principles and
are strongly aligned with the long-term interests of our stockholders. We strive to administer our compensation program in a manner that
is consistent and free of discrimination. Please read the “Executive and Director Compensation” section for additional details
about our executive compensation programs, including information about the compensation of our named executive officers.

We are asking our stockholders
to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known
as a “say-on-pay” proposal, gives our stockholders the opportunity to express their views on our named executive officers’
compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our